In Singapore our business is spread across four sites – two global manufacturing supply sites, a vaccines manufacturing facility and our corporate and commercial offices.
Address: 150 Beach Road, #21-00 Gateway West, Singapore 189720
Type: Corporate and Commercial Offices
Gateway houses the regional headquarters of our Emerging Markets and Asia Pacific pharmaceutical, consumer healthcare and ViiV businesses. It is also the global headquarters of our Established Products, Nutrition and Pain Management teams and home to our commercial operations for the local Singapore market.
Address: 38 Quality Road, Singapore 618809
Type: Global Manufacturing Site
Quality Road is one of the world’s largest amoxicillin facilities and Singapore’s first pharmaceuticals manufacturing plant. Built in 1972 at a cost of over S$32 million, the site was officially opened in May 1973 by then Finance Minister, Mr Hon Sui Sen.
The Quality Road site was originally built to produce a range of newly discovered semi-synthetic penicillin and had both primary and secondary production facilities to make the final dose forms. Over time, it became GSK's single source of amoxicillin and monosodium ticarcillin, the active compounds used in several of GSK's antibiotics widely prescribed for the treatment of bacterial infections.
To celebrate Quality Road's 40th anniversary in 2012, GSK committed to invest a further S$60 million to improve antibiotic manufacturing capabilities at the site. This enhanced process will utilize enzymatic technology to replace existing chemical processes during the production of amoxicillin. This will enable the site to maintain high standards of product quality but at a reduced cost and with significantly lower environmental impact.
Address: 1 Pioneer Sector 1, Singapore 628413
Type: Global Manufacturing Site
Part of GSK's Global Manufacturing & Supply (GMS) network, the Pioneer Sector 1 Jurong facility manufactures active pharmaceutical ingredients (APIs) used in a variety of GSK prescription medicines.
Officially opened in October 1982 by Dr Tony Tan Keng Yam, who was then Singapore's Minister for Trade and Industry, the site was initially designed to make all five stages of ranitidine hydrochloride, the active compound for a prescription medicine to treat gastric ulcers. Since then, additional production capacity has been added to the site, including an R&D pilot plant.
The site has evolved from bulk manufacture of established products in the early days to become a lead NPI (New Product Introductions) site within GSK's GMS network, focused on the development of late phase NCEs (New Chemical Entities) and delivering higher value products such as very active compounds in small batch sizes.
The site currently has three production buildings making 16 APIs (Active Pharmaceutical Ingredients) for a range of medicines prescribed for the treatment of respiratory, HIV, gastro-intestinal, allergy, anti-viral and neurological conditions.
Jurong is the prototype for GSK's Factory of the Future. To coincide with the site's 30th anniversary in 2012, GSK committed a further S$50 million to the initiative which seeks to reduce the company's carbon footprint through the use of a number of sustainable processes and green technologies.
The site has successfully adopted a dual-purpose combined technology to integrate waste heat and solvent recovery technologies into a complete system, which together with our various energy reduction projects will contribute to a 30% reduction in GSK's carbon footprint by 2020 (2010 baseline).
In 2014, the site won the coveted SEC-CDL Outstanding Singapore Environmental Achievement Award and the SEC-Setsco Singapore Environmental Achievement Award for Manufacturing, both of which were presented at the 17th Singapore Environmental Achievement Awards.
In the same year, GSK announced a further investment to build a commercial continuous processing plant using new hybrid continuous-batch synthesis. The first of its kind within GSK's GMS network, the new synthesis will shrink the number of discrete chemical stages used to manufacture an API used in medicines to treat respiratory conditions.
Address: 10 Tuas South Ave 8, Singapore 637421
Type: Global Vaccines Manufacturing Facility
With an investment of S$510 million, GSK's state-of-the-art vaccines manufacturing facility at Tuas was opened in June 2009 by Singapore's Prime Minister Lee Hsien Loong, coinciding with GSK's 50th anniversary in Singapore.
Comprising two production buildings, an administration block, quality control laboratories, a power plant and warehousing, the facility became operational in 2011. It now operates around-the-clock to manufacture purified bulk polysaccharides and conjugates, the active ingredient used to make GSK's pneumococcal conjugate vaccine. Tuas is one of only two GSK global vaccines manufacturing facilities worldwide - the other in Belgium - producing this active ingredient which is ultimately used to vaccinate children against pneumonia.
GSK is committed to continuously investing in its vaccine manufacturing facilities, improving processes and building partnerships to meet the growing global needs for high quality vaccines. As such, capacity at Tuas is being doubled and the facility is well on its way to becoming a GSK Centre of Excellence for the production of polysaccharide-based vaccines and their conjugates.
Production of HiB (Haemophilus influenzae type B) antigens, an active ingredient used in the manufacture of several vaccines, is currently being transferred to Tuas. On completion, the facility will be responsible for more than 20% of GSK’s total vaccines production.
In 2013, our Tuas Vaccines manufacturing facility installed a tri-generation plant which uses waste energy generated in the production of electricity for heating and cooling. This has improved energy efficiency by 15 – 20%, an achievement recognized by the Singapore Energy Efficiency National Partnerships Awards in the Best Practice Category.